Literature DB >> 19386705

Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex.

Zhe Liu1, Feng Yang, Jason M Robotham, Hengli Tang.   

Abstract

Replication of hepatitis C virus (HCV) RNA occurs on intracellular membranes, and the replication complex (RC) contains viral RNA, nonstructural proteins, and cellular cofactors. We previously demonstrated that cyclophilin A (CyPA) is an essential cofactor for HCV infection and the intracellular target of cyclosporine's anti-HCV effect. Here we investigate the mechanism by which CyPA facilitates HCV replication. Cyclosporine treatment specifically blocked the incorporation of NS5B into the RC without affecting either the total protein level or the membrane association of the protein. Other nonstructural proteins or viral RNAs in the RC were not affected. NS5B from the cyclosporine-resistant replicon was resistant to this disruption of RC incorporation. We also isolated membrane fractions from both naïve and HCV-positive cells and found that CyPA is recruited into membrane fractions in HCV-replicating cells via an interaction with RC-associated NS5B, which is sensitive to cyclosporine treatment. Finally, we introduced point mutations in the prolyl-peptidyl isomerase (PPIase) motif of CyPA and demonstrated a critical role of this motif in HCV replication in cDNA rescue experiments. We propose a model in which the incorporation of the HCV polymerase into the RC depends on its interaction with a cellular chaperone protein and in which cyclosporine inhibits HCV replication by blocking this critical interaction and the PPIase activity of CyPA. Our results provide a mechanism of action for the cyclosporine-mediated inhibition of HCV and identify a critical role of CyPA's PPIase activity in the proper assembly and function of the HCV RC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386705      PMCID: PMC2698523          DOI: 10.1128/JVI.02550-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Authors:  Zhaohui Cai; Chen Zhang; Kyung-Soo Chang; Jieyun Jiang; Byung-Chul Ahn; Takaji Wakita; T Jake Liang; Guangxiang Luo
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.

Authors:  Mina Nakagawa; Naoya Sakamoto; Yoko Tanabe; Tomoyuki Koyama; Yasuhiro Itsui; Yoshie Takeda; Cheng-Hsin Chen; Sei Kakinuma; Shinya Oooka; Shinya Maekawa; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

4.  Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A.

Authors:  E R Price; M Jin; D Lim; S Pati; C T Walsh; F D McKeon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

6.  Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding.

Authors:  Michael Stahl; Jürgen Beck; Michael Nassal
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.

Authors:  J Luban; K L Bossolt; E K Franke; G V Kalpana; S P Goff
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

8.  Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity.

Authors:  Yukihiro Shirota; Hong Luo; Weiping Qin; Shuichi Kaneko; Tatsuya Yamashita; Kenichi Kobayashi; Seishi Murakami
Journal:  J Biol Chem       Date:  2002-01-18       Impact factor: 5.157

9.  Subversion of cellular autophagosomal machinery by RNA viruses.

Authors:  William T Jackson; Thomas H Giddings; Matthew P Taylor; Sara Mulinyawe; Marlene Rabinovitch; Ron R Kopito; Karla Kirkegaard
Journal:  PLoS Biol       Date:  2005-04-26       Impact factor: 8.029

10.  Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.

Authors:  Nicole Appel; Margarita Zayas; Sven Miller; Jacomine Krijnse-Locker; Torsten Schaller; Peter Friebe; Stephanie Kallis; Ulrike Engel; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2008-03-28       Impact factor: 6.823

View more
  78 in total

1.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

Review 2.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

3.  Hepatitis C virus replication compartment formation: mechanism and drug target.

Authors:  Vineela Chukkapalli; Glenn Randall
Journal:  Gastroenterology       Date:  2014-03-25       Impact factor: 22.682

4.  Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.

Authors:  Chunlong Ma; Fang Li; Rami Ghassan Musharrafieh; Jun Wang
Journal:  Antiviral Res       Date:  2016-07-28       Impact factor: 5.970

Review 5.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

6.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

7.  A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Authors:  Feng Yang; Jason M Robotham; Henry Grise; Stephen Frausto; Vanesa Madan; Margarita Zayas; Ralf Bartenschlager; Margaret Robinson; Andrew E Greenstein; Anita Nag; Timothy M Logan; Ewa Bienkiewicz; Hengli Tang
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

8.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 9.  The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.

Authors:  You Li; Daisuke Yamane; Takahiro Masaki; Stanley M Lemon
Journal:  Nat Rev Microbiol       Date:  2015-08-10       Impact factor: 60.633

10.  Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Authors:  Artur Kaul; Sarah Stauffer; Carola Berger; Thomas Pertel; Jennifer Schmitt; Stephanie Kallis; Margarita Zayas; Margarita Zayas Lopez; Volker Lohmann; Jeremy Luban; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.